Litcius/Paper detail

Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

Diya Surie, Levi N. Bonnell, Katherine Adams, Manjusha Gaglani, Adit A. Ginde, David J. Douin, H. Keipp Talbot, Jonathan D. Casey, Nicholas M. Mohr, Anne Zepeski, Tresa McNeal, Shekhar Ghamande, Kevin W. Gibbs, D. Clark Files, David N. Hager, Arber Shehu, Anne Frosch, Heidi L. Erickson, Michelle N. Gong, Amira Mohamed, Nicholas J. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Ithan D. Peltan, Samuel M. Brown, Emily T. Martin, Akram Khan, William S. Bender, Abhijit Duggal, Jennifer G. Wilson, Nida Qadir, Steven Y. Chang, Christopher Mallow, Carolina Rivas, Jennie H. Kwon, Matthew C. Exline, Adam S. Lauring, Nathan I. Shapiro, Natasha Halasa, James D. Chappell, Carlos G. Grijalva, Todd W. Rice, William B. Stubblefield, Adrienne Baughman, Kelsey N. Womack, Kimberly W. Hart, Sydney A. Swan, Yuwei Zhu, Jennifer DeCuir, Mark W. Tenforde, Manish M. Patel, Meredith McMorrow, Wesley H. Self, IVY Network, IVY Network, Nicole Calhoun, Judy Herrick, Eric Hoffman, Amanda McKillop, Kempapura Murthy, Michael Smith, Martha Zayed, Lesley De Souza, Lori-Ann Kozikowski, Scott Ouellette, Kiran Ashok, Susan Gole, Alexander H. King, Omar Mehkri, Bryan Poynter, Caitlin ten Lohuis, Nicholas Stanley, Sean Caspers, Audrey Hendrickson, Olivia Kaus, Leyla Taghizadeh, Walker Tordsen, Valerie Aston, Robert R. Bowers, Jeffrey L. Jorgensen, Jennifer King, Harith Ali, Richard E. Rothman, Jen-Ting Chen, R. Nair, Gopal Allada, Genesis Briceño, Shewit P. Giovanni, Kinsley Hubel, Jesús Martínez, Minn Oh, Jonathan Pak, José Peña, Alexandra June Gordon, Joe Levitt, Cynthia M. Pérez, Jonasel Roque, Anita Visweswaran, Sarah Karow, Maryiam Khan

2022MMWR Morbidity and Mortality Weekly Report60 citationsDOIOpen Access PDF

Abstract

should receive a booster dose, which currently consists of a bivalent mRNA vaccine, to maximize protection against BA.4/BA.5 and prevent COVID-19-associated hospitalization.

Topics & Concepts

Coronavirus disease 2019 (COVID-19)VaccinationMedicineImmunitySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyImmunologyInternal medicineImmune systemInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies
Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022 | Litcius